All In MedTech

Device Trial Radar · NCT06471764

Validation Study of Frontier X Plus (FX+) Device

Validation Study of Frontier X Plus (FX+) Device: Recording an Electrocardiogram (ECG) for Retrospective Rhythm Analysis in Patients with and Without Atrial Fibrillation (AF) in US Subjects

Last checked: Nov 20, 2026Latest source record: Jun 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

125

Planned (sponsor's estimate)

Start

Jul 1, 2024

Primary completion

Jan 20, 2025

Study completion Apr 20, 2025

Sponsor

Lead sponsor
Fourth Frontier Technologies Pvt Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
University of Rochester
First posted
Jun 24, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this study is to validate the specificity and sensitivity of FX+ detecting atrial fibrillation (AF) in both AF and non-AF subjects using a comparative approach, which involves using both a US FDA-cleared gold standard 12-lead and a consumer device which stores ECG (FX2 consumer model used to store the ECG for analysis retrospectively). The results obtained from this clinical investigation will serve as evidence for larger clinical investigation designs for this non-invasive and fully mobile method of continuous AF measurement in the adult population, including those with known or unknown cases of AF. The ultimate goal of this study is to establish the effectiveness of this novel approach in detecting and monitoring AF, which could potentially revolutionize the field of remote cardiac monitoring and improve the quality of care for patients with AF and other cardiac arrhythmias.

Conditions

  • Atrial Fibrillation

Interventions

  • FX+ and 12-Lead ECG RecordingDevice

    While lying down, subjects will wear the FX+, a chest strap device which will measure cardiac electrical activity to generate a continuous heart rate measurement. Simultaneously, electrodes for the 12-Lead ECG will be placed on the chest and arms/legs to record the electrical activity. Two 30-second recordings from the FX+ will be taken simultaneously with the 12-lead ECG with no more than a 3-minute interval between the two recordings.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Validation of reliability of Frontier X Plus (FX+) to produce a clinically equivalent waveform in agreement to a gold-standard 12-lead ECG's Lead-1 referenceTime frame: 6 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.